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Background: Marfan syndrome (MFS) is a rare autosomal dominantly inherited connective tissue disorder with an
estimated prevalence of 1:5,000. More than 1000 variants have been previously reported to be associated with MFS.
However, the disease-causing effect of these variants may be questionable as many of the original studies used low
number of controls. To study whether there are possible false-positive variants associated with MFS, four in silico
prediction tools (SIFT, Polyphen-2, Grantham score, and conservation across species) were used to predict the
pathogenicity of these variant.
Results: Twenty-three out of 891 previously MFS-associated variants were identified in the ESP. These variants were
distributed on 100 heterozygote carriers in 6494 screened individuals. This corresponds to a genotype prevalence of
1:65 for MFS. Using a more conservative approach (cutoff value of >2 carriers in the EPS), 10 variants affected a total
of 82 individuals. This gives a genotype prevalence of 1:79 (82:6494) in the ESP. A significantly higher frequency
of MFS-associated variants not present in the ESP were predicted to be pathogenic with the agreement of ≥3
prediction tools, compared to the variants present in the ESP (p = 3.5 × 10−15).
Conclusions: This study showed a higher genotype prevalence of MFS than expected from the phenotype
prevalence in the general population. The high genotype prevalence suggests that these variants are not the
monogenic cause of MFS. Therefore, caution should be taken with regard to disease stratification based on these
previously reported MFS-associated variants.
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Marfan syndrome (MFS; OMIM 154700), first described
by Antoine Marfan in 1898, is an autosomal dominantly
inherited connective tissue disorder with a phenotype
that involves mainly the cardiovascular, ocular, and
skeletal systems. The prevalence of MFS in the general
US and European population has been estimated to be
1:5,000 [1,2]. MFS has a high penetrance, but variable* Correspondence: yangrenqiangcn@gmail.com
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unless otherwise stated.expression [3]. Cardiovascular complications are the main
cause of premature death among MFS patients [4,5].
Besides aortic aneurysm and/or dissection, MFS can lead
to valvular heart disease [6], enlargement of the proximal
pulmonary artery [7], congestive heart failure [8], and
arrhythmias [9].
According to the current “revised Ghent nosology”,
the diagnosis of MFS should be based on clinical mani-
festation, family history, and molecular genetic testing of
the fibrillin 1 gene (FBN1 gene) and the clinical criteria
employs a set of manifestations in many tissues [10].
Approximately 25% of all MFS patients do not have a
family history and hence, represents new cases due to ded. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have been reported to be associated with MFS [11]. Re-
cently, transforming growth factor beta (TGFB) has been
found to play a pivotal role in the progression of MFS
[12]. A disease that has many similarities with Marfan
syndrome, termed Loeys-Dietz syndrome, was identified
to be caused by variants in the transforming growth
factor-beta type II receptor (TGFBR2) [13]. An atypical
or incomplete MFS has also been described in some pa-
tients caused by genetic variants in transforming growth
factor-beta type I receptor (TGFBR1) and TGFBR2 [14].
However, to our knowledge, there are no systematic
studies focusing on separating genetic noise from disease-
causing variations by identifying variants previously asso-
ciated with MFS in large-scale populations.
Until recently, there has only been little knowledge
regarding the distribution of genetic variations in general
population, especially with regard to low-frequency vari-
ants of MFS. This is potentially a problem, when rare
variants are associated with MFS because of the risk of
false-positive findings. The disease-causing role of some
of these variants is questionable as many of these studies
have used low number of controls. This problem has
now partly been solved with the release of exome data
from the NHLBI GO Exome Sequencing Project (ESP).
Large-scale surveys of human genetic variations provide
an important chance to identify causative variants, not-
able for an excess of rare genetic variants [15].
The aim of this study was to identify false positive vari-
ants previously associated with Marfan syndrome. This is
important since genetic testing today is used in order to
confirm MFS diagnose according to the revised Ghent
Nosology. In the absence of family history and aortic root
dilatation/dissection, but presence of ectopialentis, the
identification of an FBN1 variant previously associated
with aortic disease is required in making the diagnosis.
Also in the absence of family history and ectopialentis, but
presence of aortic root dilatation/dissection a genetic test
for identification of mutation in FBN1 is sufficient to
establish a MFS diagnosis. Due to the importance of a
positive genetic finding in patients suspected of MFS,
identification of false positive variants has major clinical
implications. Furthermore, we aimed to provide compre-
hensive in silico prediction analysis to all MFS-associated
variants, in order to better classify the impact of the varia-
tions on the encoded proteins.
Methods
In the ESP, next-generation sequencing was carried out
for all protein-coding regions in 6,503 individuals from
different population studies [16]. It currently contains
2,203 unrelated African-Americans (AA) and 4,300 un-
related European-Americans (EA) (13,006 alleles in
total). In the ESP database, samples were selected tocontain healthy controls, the extremes of specific traits
(LDL and blood pressure), and specific diseases (early
onset myocardial infarction and early onset stroke), and
lung diseases. To our knowledge, patients with MFS
have not been included intentional in ESP. Clinical data
were not available, nor on request.
To find all genes and variants associated with MFS, a
search for missense and nonsense variants was per-
formed in the Human Gene Mutation Database (HGMD
Professional 2013.2) [17]. Additionally, the following lit-
erature search query was used in the PubMed database
((Marfan) OR (Marfan syndrome) or (“Marfan syndrome”
[Mesh])) AND ((Genetic) OR (“Genetics” [Mesh])) AND
((mutation) OR (variant)). In this way, we included 3
variants recently associated with MFS [18-20]. Finally, we
searched the ESP for all these variants (Version: v.0.0.20.
(June 7, 2013)). We used a terminology so that MFS-
associated variants identified in the ESP database are
termed ESP-Positive variants and variants not identified in
ESP as ESP-Negative variants. Because of lack of data
regarding introns and untranslated regions in the ESP,
variants in introns and untranslated regions could not
be included. Furthermore, we did not include variants
in the genes COL1A2 and LTBP2, since variants in these
genes have not been convincingly associated with MFS.
Since the aim of this study was to include all possible
variants previously associated with MFS, we also in-
cluded variants which were associated with MFS using
the old Ghent criteria.
Based on the phenotype prevalence of MFS (1/5000 =
0.02%), the expected prevalence of MFS in the ESP popu-
lation is 0.02% (95% CI 0.0%-0.05%) for 1.3 subjects out of
6503.
Therefore, estimated number of individuals affected by
MFS in the ESP can be expected to be no more than 2.
That is, a given variant with complete penetrance should
theoretically not affect more than 2 ESP alleles in order to
be the cause of a monogenic form of MFS. For a conserva-
tive approach, we therefore used a cutoff value of >2 af-
fected the ESP alleles, to estimate the genotype prevalence
of MFS.
The literature was searched for functional data and
familial co-segregation of all the MFS-associated ESP-
Positive variants. Familial co-segregation was defined as
at least two family members having the same genotype
as well as the same MFS phenotype.
Four traditional prediction tools (SIFT,Polyphen-2,
Grantham score, and conservation across species) were
applied in order to predict the pathogenicity of all MFS-
associated missense variants. Nonsense variants that were
assumed “probably damaging” were not included in the
prediction analyses. Missense variants were classified as
damaging if they were predicted to be damaging by ≥3 of
the four applied prediction tools [21]. Conservation across
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have been preserved during the evolution. For more
detail, please see online Additional file 1. The list of
ESP-Negative variants is shown in the Additional file 2:
Table S1. Any difference in the proportion of variants
predicted to be damaging for ESP-Positive variants
compared with ESP-Negative variants was assessed
with the Fisher’s exact. A two-tailed P-value <0.05 was
considered statistical significant.Results
Variants associated with MFS
Three genes have been previously reported to be in-
volved in MFS: FBN1, TGFBR1, and TGFBR2. In FBN1,
TGFBR1, and TGFBR2, a total of 891 missense/non-
sense variants have been reported to be associated with
MFS. There are737missense and 154 nonsense variants
associated with MFS. Overall, 97% (861/891) of all vari-
ants were found in FBN1, less than 3% (26/891) and less
than 1% (4/891) was found in TGFBR2and TGFBR1,










c.59A > G# p.Y20C 0 3 4293
c.1027G > A# p.G343R 0 2 4294
c.1345G > A# p.V449I 0 2 4294
c.2056G > A# p.A686T 0 0 4296
c.2927G > A# p.R976H 0 2 4294
c.3058A > G# p.T1020A 0 3 4293
c.3422C > T p.P1141L 0 13 4283
c.3509G > A# p.R1170H 0 23 4273
c.3797A > T# p.Y1266F 0 4 4292
c.3845A > G# p.N1282S 0 2 4294
c.4270C > G p.P1424A 0 4 4292
FBN1 c.6055G > A p.E2019K 0 1 4295
c.6700G > A# p.V2234M 0 8 4288
c.7241G > A# p.R2414Q 0 1 4295
c.7379A > G# p.K2460R 0 2 4294
c.7660C > T# p.R2554W 0 1 4295
c.7661G > A# p.R2554Q 0 1 4295
c.7702G > A# p.V2568M 0 0 4296
c.7846A > G# p.I2616V 0 3 4293
c.7852G > A# p.G2618R 0 1 4295
c.8081G > A# p.R2694Q 0 1 4295
c.8176C > T# p.R2726W 0 9 4287
c.8494A > G# p.S2832G 0 1 4295
ESP: Exome Sequencing Project. #The variant was reported as a novel variant in theThe ESP-positive variants
Twenty-three out of the 891 variants previously associ-
ated with MFS were identified in the ESP population. All
of the 23ESP-positive variants were missense variants
found in the FBN1 gene, and 87% (20/23) of these vari-
ants have been reported as novel mutations in the pub-
lished original papers. In total, 100 heterozygote carriers
of these 23variants were present in the ESP. The FBN1
gene was screened in 6,494 individuals on average in the
ESP. This corresponds to a genotype prevalence of 1:65
(100:6494) in the ESP (Table 1). This is a very large
overrepresentation of MFS associated variants; hence, it
is likely that many of these variants are not the major/
monogenic cause of MFS.
Using a more conservative approach (cutoff value of >2
present in the EPS), 10 out of the 23 variants were present
in three or more individuals in the ESP. These variants
affected a total of 82 individuals giving a genotype
prevalence of 1:79 (82:6494). The remaining 13 variants
are rare non-synonymous variants (<=2), affecting 18
individuals in the ESP, giving a genotype prevalence of
1:361 (18:6494) (Table 1).difference distribution of one allele in the ESP population













0 0 2197 0 3 6490 [1]
0 0 2197 0 2 6491 [22]
0 0 2197 0 2 6491 [23]
0 1 2196 0 1 6492 [24]
0 0 2198 0 2 6492 [25]
0 0 2198 0 3 6491 [26]
0 1 2197 0 14 6480 [27]
0 2 2196 0 25 6469 [28]
0 0 2198 0 4 6490 [29]
0 1 2197 0 3 6491 [30]
0 0 2198 0 4 6490 [31]
0 0 2198 0 1 6493 [32]
0 0 2198 0 8 6486 [22]
0 0 2198 0 1 6493 [33]
0 0 2198 0 2 6492 [34]
0 0 2198 0 1 6493 [25]
0 0 2198 0 1 6493 [32]
0 1 2197 0 1 6493 [34]
0 1 2197 0 4 6490 [34]
0 1 2197 0 2 6492 [29]
0 0 2198 0 1 6493 [24]
0 5 2193 0 14 6480 [35]
0 0 2198 0 1 6493 [24]
paper.
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(23/861) were present in the ESP. Family co-segregation
and functional characterization data of all the 23 variants
are present in Table 2. Most of MFS-associated variants
were ESP-Negative variants. None of MFS- associated
variants in TGFBR1 and TGFBR2 was identified in the
ESP population. Furthermore, clinical data for these 23
patients is shown in Additional file 3: Table S2.
In order to test if the ESP data harbored an over repre-
sentation, one variant TGFBR2 V387M (rs35766612),
previously reported to be involved in the patient with
Marfanoid features [36], was genotyped in our own
healthy Northern European control population (n = 704).
There were 30 carriers of this variant in 6504 individuals
on average in the ESP population. We found 4 carriers in
our healthy population. The genotype prevalence of the
variant in our healthy control population was comparable
with that in the ESP (4:750 vs.30:6503, p = 0.578).Prediction analyses of the ESP-positive variants vs. the
ESP-negative variants
Using SIFT prediction, 26% (6/23) of the ESP-Positive
variants were predicted to be damaging, compared
with86% (613/713) of the ESP-Negative variants (p =
4.1 × 10−10). Using Polyphen-2 prediction tool, the vari-
ants present in the ESP were predicted pathogenic in
39% (9/23) of the cases compared with 94% (670/713) of
the ESP-Negative variants (p = 2.8 × 10−11). Using the
Grantham scores, 22% (5/23) of the ESP-Positive vari-
ants were predicted to be damaging compared with 72%
(516/713) of the ESP-Negative variants (p = 1.1 × 10−6).
Finally, we used Conservation across species and found
that 61% (14/23) of the ESP-Positive variants were identi-
fied in a conserved region, predicted as damaging, com-
pared with 92% (659/713) of the ESP-Negative variants
(p = 4.5 × 10−5). The calculation of the agreement of ≥3
pathogenicity predictions showed that 13% (3/23) of
variants present in the ESP and 88% (627/713) of the
ESP-Negative variants were predicted to be damaging
(p = 3.5 × 10−15) (Figure 1). For more details, please see
the online Additional file 2. Same trend was found when
the ESP positive was divided into whether they occurred
more or less than two times in the ESP (online Additional
file 4: Figure S1).Discussion
The present study is the first to report and critically
evaluate the genetic background noise in Marfan syn-
drome based on the prevalence of previously reported
MFS-associated genetic variants in the ESP database.
We found a much higher prevalence (1:65) of MFS-
associated genetic variants in the ESP than expected
according to the phenotype prevalence of 1:5,000 in thegeneral US and European population. The ESP data is
thought to be representative for this population.
In order to test if the ESP data harbored an over repre-
sentation, one variantTGFBR2 V387M (rs35766612), previ-
ously reported to be involved in the patient with Marfanoid
features [36], was genotyped in our own healthy Northern
European control population (n = 704). There were 30
carriers of this variant in 6,504 individuals on average in the
ESP population. We found 4 carriers in our healthy popula-
tion. The genotype prevalence of the variant in our healthy
control population was comparable with that in the ESP
(4:750 vs.30:6503, p = 0.578). For more details, please see
the online Additional file 1. Recent papers have also estab-
lished the prevalence of other rare variants genotyped in
our Northern European control population and found
that they were comparable to those of the ESP [37-39].
This is suggesting that it is unlikely that the ESP popula-
tion harbor a major overrepresentation of some of the
MFS-associated variants.
A prevalence like this is however unlikely to be caused
by reduced penetrance or age-related delayed presenta-
tion of the disease, as MFS has a high penetrance with
onset of symptoms early in life [3].
It is likely that some of these variants are either not a
monogenic cause of MFS, or they have incomplete pene-
trance. Lucarini et al. [40] screened the TGFBR1 gene in
patients with MFS who were excluded as carriers of the
variants in FBN1 and TGFBR2. Their findings suggested
that some variants are overrepresented in MSF patients
compared to control suggesting that TGFBR1 may be
the underlying genetic cause of MSF, but with low
penetrance alleles in MFS.
Four common prediction tools were applied to evaluate
the phylogenetic and physicochemical effects on the MFS-
associated variants. Recently published data support the
potential clinical utility of these tools [21]. In our study,
we found that a much lower proportion of the ESP-
Positive variants were predicted to be damaging compared
with those ESP-Negative variants (13% vs. 88%, p =3.5 ×
10−15, Figure 1). This result further questions the patho-
genic role of at least some of the variants present in the
ESP. But it does not definitively exclude the possibility of
pathogenicity. Some ESP-Positive variants in low fre-
quency could potentially be disease causing. Accordingly,
the presence of a variant in the ESP population does not
exclude that the variant might be disease-causing, but is
indeed questioning the variant disease causing potential,
particularly when the variant presents in the ESP in high
frequency. The same approach and concerns were re-
cently also suggested in another disease; catecholaminer-
gic polymorphic ventricular tachycardia [41].
We defined a cutoff value (>2) in the ESP (n = 6503)
based on the expected prevalence of MFS (1:5,000). This
cutoff is of course somewhat arbitrary because we do
Table 2 Functional data and family co-segregation for genes and variants in the ESP population
Gene Variant dbSNP All genotypes (EA + AA) SIFT PolyPhen-2 Grantham score Conservation Agreement HGMD Family Functional data
YES/NO ≥3 Variant class Co-segregation
c.59A > G rs201309310 CC = 0/CT = 3/TT = 6490 Tolerant Benign D (194) YES B DM YES NO
c.1027G > A rs146726731 TT = 0/TC = 2/CC = 6491 Tolerant Possibly damaging D (125) YES D DM NO NO
c.1345G > A rs139058991 TT = 0/TC = 2/CC = 6491 Tolerant Benign B (29) YES B DM NO NO
c.2056G > A rs377621293 TT = 0/TC = 1/CC = 6492 Tolerant Benign B (58) YES B DM NO NO
c.2927G > A rs140954477 TT = 0/TC = 2/CC = 6492 Tolerant Probably damaging B (29) YES B DM NO NO
c.3058A > G rs111801777 CC = 0/CT = 3/TT = 6491 Tolerant Benign B (58) NO B DM NO NO
c.3422C > T rs2228241 AA = 0/AG = 14/GG = 6480 Damaging Probably damaging B (98) NO B DM? NO NO
c.3509G > A rs137854475 TT = 0/TC = 25/CC = 6469 Tolerant Benign B (29) YES B DM YES NO
c.3797A > T rs200283837 AA = 0/AT = 4/TT = 6490 Tolerant Benign B (22) NO B DM NO NO
c.3845A > G rs140647 CC = 0/CT = 3/TT = 6491 Damaging Benign B (46) YES B DM? NO NO
c.4270C > G rs201273753 CC = 0/CG = 4/GG = 6490 Damaging Probably damaging B (27) NO B DM NO NO
FBN1 c.6055G > A rs377149130 TT = 0/TC = 1/CC = 6493 Tolerant Possibly damaging B (56) NO B DM? YES NO
c.6700G > A rs112084407 TT = 0/TC = 8/CC = 6486 Tolerant Benign B (21) NO B DM NO NO
c.7241G > A rs143863014 TT = 0/TC = 1/CC = 6493 Tolerant Benign B (43) NO B DM YES NO
c.7379A > G rs144189837 CC = 0/CT = 2/TT = 6492 Tolerant Possibly damaging B (26) YES B DM NO NO
c.7660C > T rs369294972 AA = 0/AG = 1/GG = 6493 Damaging Probably damaging D (101) YES D DM YES NO
c.7661G > A rs199522781 TT = 0/TC = 1/CC = 6493 Tolerant Probably damaging B (43) YES B DM? NO NO
c.7702G > A rs138558987 TT = 0/TC = 1/CC = 6493 Damaging Benign B (21) YES B DM NO NO
c.7846A > G rs143677764 CC = 0/CT = 4/TT = 6490 Tolerant Benign B (29) NO B DM YES NO
c.7852G > A rs141133182 TT = 0/TC = 2/CC = 6492 Tolerant Probably damaging D (125) YES D DM NO NO
c.8081G > A rs371375126 TT = 0/TC = 1/CC = 6493 Tolerant Benign B (43) YES B DM NO NO
c.8176C > T rs61746008 AA = 0/AG = 14/GG = 6480 Damaging Benign D (101) NO B DM YES NO
c.8494A > G rs376933421 CC = 0/CT = 1/TT = 6493 Tolerant Benign B (56) YES B DM NO NO


















Figure 1 Percentage of variants predicted to be pathogenic with four In silico tools prediction on variants present and not present in
ESP database. Differences in proportions of variants predicted to be damaging for those variants present in ESP versus variants not present in
ESP were assessed using Fisher’s exact test. *p = 4.1 × 10−10, **p = 2.8 × 10−11, ***p = 1.1 × 10−6, ****p = 4.5 × 10−5, *****p = 3.5 × 10−15.
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lation. So assuming that MFS is a monogenic disorder,
the findings of some variants with prevalence above the
cutoff value of more than 2 in the ESP suggest that some
of the variants at least may be false-positive, or incom-
plete penetrance. Reduced or incomplete penetrance is
not uncommon in genetic diseases. It can be resulted
from differential allelic expression or copy number vari-
ation [42]. The interpretation of variants with a preva-
lence below a certain cutoff value in the ESP may be
considered monogenic disease-causing, disease-modifier
or benign.
Genetic screening is gaining ground in the diagnostic
workup of families and identification of populations at a
high risk of suffering an inherited disease [43]. Accord-
ing to “the revised Ghent nosology”, genetic screening
for variants may in some cases be the game changer in
making the diagnose MFS [10].
Genetic screening for MFS in family members has
become an important tool in family cascade screening.
In particular, targeted testing of FBN1 is recommended
in cases where MFS is suspected following a cardiac
examination. It is noteworthy, that only 23 out of 861
(3%) variants in FBN1 were identified in the ESP. That
is, 97% of the variants in FBN1were not among nearly
6,500 subjects in the ESP. This confirms the pivotal role
and usefulness of the FBN1 gene in genetic screening.
Awareness of an FBN1 variant should imply for in-
creased vigilance for MFS. Treatment with an angioten-
sin receptor blocker has been proven to be effective in
reducing rates of aortic root dilatation in MFS patients.
So knowledge of an FBN-1 variant may allow actionableinterventions earlier in the natural history of the condi-
tion [5].
Lack of properly scaled control populations has always
been a problem when dealing with low frequency genetic
variations of rare monogenetic diseases. Without a rea-
sonable control population we might misdiagnose family
members undergoing genetic testing and follow-up.
Based on our study, we strongly suggest that exome
data, like the ESP, should be used as empirical data in
research and clinical practice, alongside with known pre-
diction tools to get a more exact understanding of the
pathogenicity of the variants associated with MFS or
other rare inherited disorders. It is important to keep in
mind that the absence of variants in the ESP in itself, is
not to be interpreted as the variant is disease causing,
but certainly strengthen the possibility. Furthermore the
Marfan-related mutations analyses in this study do not
exclude that further potentially false-positive variants
could be found in healthy persons in other populations
such as Asians. Comparing findings in this study with
other populations may reduce the rate of false positive
variants.Conclusion
In this study we have identified 23 previously reported
MFS-associated variants in the ESP database. The geno-
type prevalence of these variants corresponded to MFS
prevalence of 1:65. The high genotype prevalence ques-
tions the causality of some of these variants, suggesting
that these variants may not be the monogenic cause of
MFS. Therefore, caution should be taken with regard to
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ated with MFS.
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